<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Genet Med</journal-id>
<journal-id journal-id-type="iso-abbrev">Genet. Med</journal-id>
<journal-title-group>
<journal-title>Genetics in Medicine</journal-title>
</journal-title-group>
<issn pub-type="ppub">1098-3600</issn>
<issn pub-type="epub">1530-0366</issn>
<publisher>
<publisher-name>Nature Publishing Group US</publisher-name>
<publisher-loc>New York</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">31182824</article-id>
<article-id pub-id-type="pmc">6831729</article-id>
<article-id pub-id-type="publisher-id">554</article-id>
<article-id pub-id-type="doi">10.1038/s41436-019-0554-6</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Systematic Review</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Meta-analysis and multidisciplinary consensus statement: exome
sequencing is a first-tier clinical diagnostic test for individuals with
neurodevelopmental disorders</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Srivastava</surname>
<given-names>Siddharth</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="Aff1">1</xref>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-4928-4078</contrib-id>
<name>
<surname>Love-Nichols</surname>
<given-names>Jamie A.</given-names>
</name>
<degrees>MS, MPH</degrees>
<xref ref-type="aff" rid="Aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Dies</surname>
<given-names>Kira A.</given-names>
</name>
<degrees>ScM</degrees>
<xref ref-type="aff" rid="Aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-8934-4210</contrib-id>
<name>
<surname>Ledbetter</surname>
<given-names>David H.</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="Aff2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Martin</surname>
<given-names>Christa L.</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="Aff2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Chung</surname>
<given-names>Wendy K.</given-names>
</name>
<degrees>MD, PhD</degrees>
<xref ref-type="aff" rid="Aff3">3</xref>
<xref ref-type="aff" rid="Aff4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Firth</surname>
<given-names>Helen V.</given-names>
</name>
<degrees>DM, FRCP</degrees>
<xref ref-type="aff" rid="Aff5">5</xref>
<xref ref-type="aff" rid="Aff6">6</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Frazier</surname>
<given-names>Thomas</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="Aff7">7</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hansen</surname>
<given-names>Robin L.</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="Aff8">8</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Prock</surname>
<given-names>Lisa</given-names>
</name>
<degrees>MD, MPH</degrees>
<xref ref-type="aff" rid="Aff1">1</xref>
<xref ref-type="aff" rid="Aff9">9</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Brunner</surname>
<given-names>Han</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="Aff10">10</xref>
<xref ref-type="aff" rid="Aff11">11</xref>
<xref ref-type="aff" rid="Aff12">12</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hoang</surname>
<given-names>Ny</given-names>
</name>
<degrees>MS</degrees>
<xref ref-type="aff" rid="Aff13">13</xref>
<xref ref-type="aff" rid="Aff14">14</xref>
<xref ref-type="aff" rid="Aff15">15</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-8326-1999</contrib-id>
<name>
<surname>Scherer</surname>
<given-names>Stephen W.</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="Aff14">14</xref>
<xref ref-type="aff" rid="Aff15">15</xref>
<xref ref-type="aff" rid="Aff16">16</xref>
<xref ref-type="aff" rid="Aff17">17</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-7044-2953</contrib-id>
<name>
<surname>Sahin</surname>
<given-names>Mustafa</given-names>
</name>
<degrees>MD PhD</degrees>
<address>
<email>mustafa.sahin@childrens.harvard.edu</email>
</address>
<xref ref-type="aff" rid="Aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-1060-1945</contrib-id>
<name>
<surname>Miller</surname>
<given-names>David T.</given-names>
</name>
<degrees>MD PhD</degrees>
<xref ref-type="aff" rid="Aff18">18</xref>
</contrib>
<contrib contrib-type="author">
<collab>the NDD Exome Scoping Review Work
Group</collab>
</contrib>
<aff id="Aff1"><label>1</label>Translational Neuroscience Center, Department of
Neurology, Boston Children’s Hospital, Harvard Medical School, Boston, MA USA </aff>
<aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.476963.9</institution-id><institution>Autism &amp; Developmental Medicine Institute, Geisinger, </institution></institution-wrap>Danville, PA USA </aff>
<aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000000419368729</institution-id><institution-id institution-id-type="GRID">grid.21729.3f</institution-id><institution>Departments of Pediatrics and Medicine, </institution><institution>Columbia University, </institution></institution-wrap>New York, NY USA </aff>
<aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="GRID">grid.430264.7</institution-id><institution>SFARI, Simons Foundation, </institution></institution-wrap>New York, NY USA </aff>
<aff id="Aff5"><label>5</label>Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge UK </aff>
<aff id="Aff6"><label>6</label>East Anglian Medical Genetics Service, Cambridge University Hospitals
NHS Foundation Trust, Cambridge Biomedical Campus, Cambridge, UK </aff>
<aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 4663 7867</institution-id><institution-id institution-id-type="GRID">grid.427598.5</institution-id><institution>Autism Speaks, </institution></institution-wrap>Cleveland, OH USA </aff>
<aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1936 9684</institution-id><institution-id institution-id-type="GRID">grid.27860.3b</institution-id><institution>MIND Institute, Department of Pediatrics, </institution><institution>University of California Davis, </institution></institution-wrap>Sacramento, CA USA </aff>
<aff id="Aff9"><label>9</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0378 8438</institution-id><institution-id institution-id-type="GRID">grid.2515.3</institution-id><institution>Developmental Medicine Center, </institution><institution>Boston Children’s Hospital, </institution></institution-wrap>Boston, MA USA </aff>
<aff id="Aff10"><label>10</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0444 9382</institution-id><institution-id institution-id-type="GRID">grid.10417.33</institution-id><institution>Department of Human Genetics, </institution><institution>Radboud University Medical Center, </institution></institution-wrap>Nijmegen, The Netherlands </aff>
<aff id="Aff11"><label>11</label><institution-wrap><institution-id institution-id-type="ISNI">0000000122931605</institution-id><institution-id institution-id-type="GRID">grid.5590.9</institution-id><institution>Donders Institute for Brain, Cognition and Behaviour, </institution><institution>Radboud University, </institution></institution-wrap>Nijmegen, The Netherlands </aff>
<aff id="Aff12"><label>12</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0480 1382</institution-id><institution-id institution-id-type="GRID">grid.412966.e</institution-id><institution>The Netherlands; Department of Clinical Genetics and GROW-School for
Oncology and Developmental Biology, </institution><institution>Maastricht University Medical Center, </institution></institution-wrap>Maastricht, The Netherlands </aff>
<aff id="Aff13"><label>13</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0473 9646</institution-id><institution-id institution-id-type="GRID">grid.42327.30</institution-id><institution>Department of Genetic Counselling, </institution><institution>The Hospital for Sick Children, </institution></institution-wrap>Toronto, ON Canada </aff>
<aff id="Aff14"><label>14</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0473 9646</institution-id><institution-id institution-id-type="GRID">grid.42327.30</institution-id><institution>Genetics and Genome Biology, </institution><institution>The Hospital for Sick Children, </institution></institution-wrap>Toronto, ON Canada </aff>
<aff id="Aff15"><label>15</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2157 2938</institution-id><institution-id institution-id-type="GRID">grid.17063.33</institution-id><institution>Department of Molecular Genetics, </institution><institution>University of Toronto, </institution></institution-wrap>Toronto, ON Canada </aff>
<aff id="Aff16"><label>16</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0473 9646</institution-id><institution-id institution-id-type="GRID">grid.42327.30</institution-id><institution>The Centre for Applied Genomics, </institution><institution>The Hospital for Sick Children, </institution></institution-wrap>Toronto, ON Canada </aff>
<aff id="Aff17"><label>17</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2157 2938</institution-id><institution-id institution-id-type="GRID">grid.17063.33</institution-id><institution>McLaughlin Centre and Department of Molecular Genetics, Faculty of
Medicine, </institution><institution>University of Toronto, </institution></institution-wrap>Toronto, ON Canada </aff>
<aff id="Aff18"><label>18</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0378 8438</institution-id><institution-id institution-id-type="GRID">grid.2515.3</institution-id><institution>Division of Genetics and Genomics, </institution><institution>Boston Children’s Hospital, </institution></institution-wrap>Boston, MA USA </aff>
</contrib-group>
<pub-date pub-type="epub">
<day>11</day>
<month>6</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>11</day>
<month>6</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="ppub">
<year>2019</year>
</pub-date>
<volume>21</volume>
<issue>11</issue>
<fpage>2413</fpage>
<lpage>2421</lpage>
<history>
<date date-type="received">
<day>20</day>
<month>2</month>
<year>2019</year>
</date>
<date date-type="accepted">
<day>15</day>
<month>5</month>
<year>2019</year>
</date>
</history>
<permissions>
<copyright-statement>© The Author(s) 2019</copyright-statement>
<license license-type="OpenAccess">
<license-p><bold>Open Access</bold> This article is licensed
under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0
International License, which permits any non-commercial use, sharing,
distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, and provide a link
to the Creative Commons license. You do not have permission under this license
to share adapted material derived from this article or parts of it. The images
or other third party material in this article are included in the article’s
Creative Commons license, unless indicated otherwise in a credit line to the
material. If material is not included in the article’s Creative Commons license
and your intended use is not permitted by statutory regulation or exceeds the
permitted use, you will need to obtain permission directly from the copyright
holder. To view a copy of this license, visit <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>.</license-p>
</license>
</permissions>
<abstract id="Abs1">
<sec>
<title>Purpose</title>
<p id="Par1">For neurodevelopmental disorders (NDDs), etiological evaluation can
be a diagnostic odyssey involving numerous genetic tests, underscoring the need
to develop a streamlined algorithm maximizing molecular diagnostic yield for
this clinical indication. Our objective was to compare the yield of exome
sequencing (ES) with that of chromosomal microarray (CMA), the current
first-tier test for NDDs.</p>
</sec>
<sec>
<title>Methods</title>
<p id="Par2">We performed a PubMed scoping review and meta-analysis investigating
the diagnostic yield of ES for NDDs as the basis of a consensus development
conference. We defined NDD as global developmental delay, intellectual
disability, and/or autism spectrum disorder. The consensus development
conference included input from genetics professionals, pediatric neurologists,
and developmental behavioral pediatricians.</p>
</sec>
<sec>
<title>Results</title>
<p id="Par3">After applying strict inclusion/exclusion criteria, we identified 30
articles with data on molecular diagnostic yield in individuals with isolated
NDD, or NDD plus associated conditions (such as Rett-like features). Yield of ES
was 36% overall, 31% for isolated NDD, and 53% for the NDD plus associated
conditions. ES yield for NDDs is markedly greater than previous studies of CMA
(15–20%).</p>
</sec>
<sec>
<title>Conclusion</title>
<p id="Par4">Our review demonstrates that ES consistently outperforms CMA for
evaluation of unexplained NDDs. We propose a diagnostic algorithm placing ES at
the beginning of the evaluation of unexplained NDDs.</p>
</sec>
</abstract>
<kwd-group xml:lang="en">
<title>Keywords</title>
<kwd>autism</kwd>
<kwd>consensus development conference</kwd>
<kwd>diagnostic yield</kwd>
<kwd>genetic testing</kwd>
<kwd>intellectual disability</kwd>
</kwd-group>
<funding-group>
<award-group>
<funding-source>
<institution>Wade Family Foundation</institution>
</funding-source>
<award-id>N/A</award-id>
<principal-award-recipient>
<name>
<surname>Sahin</surname>
<given-names>Mustafa</given-names>
</name>
</principal-award-recipient>
</award-group>
</funding-group>
<custom-meta-group>
<custom-meta>
<meta-name>issue-copyright-statement</meta-name>
<meta-value>© American College of Medical Genetics and Genomics 2019</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="Sec1" sec-type="introduction">
<title>INTRODUCTION</title>
<p id="Par5">Neurodevelopmental disorders (NDDs) are a heterogeneous group of
conditions that impact brain development and affect various aspects of daily
functioning. At least 30% of NDDs are thought to have a genetic
basis.<sup><xref ref-type="bibr" rid="CR1">1</xref></sup> Among these disorders, global developmental delay
(GDD)—a precursor diagnosis to intellectual disability (ID)—and autism spectrum
disorder (ASD) are two entities for which there are guidelines for genetic
testing.<sup><xref ref-type="bibr" rid="CR2">2</xref>,<xref ref-type="bibr" rid="CR3">3</xref></sup>
The 2010 guideline from the American College of Medical Genetics and Genomics (ACMG)
suggests that chromosomal microarray (CMA) and fragile X (FXS) testing should be
first-tier tests for individuals with unexplained GDD/ID and/or ASD (except for
females with ASD and normal cognition, for which FXS testing is not
recommended).<sup><xref ref-type="bibr" rid="CR3">3</xref></sup> There are also considerations for single-gene
testing of <italic>MECP2</italic> and <italic>PTEN</italic> under certain circumstances,<sup><xref ref-type="bibr" rid="CR2">2</xref></sup> although gene panels are now
typically preferred over single-gene testing. These recommendations and practices
exist because of the complex genetic heterogeneity underlying NDDs that sometimes
makes diagnostic determinations difficult based on history/examination
alone.<sup><xref ref-type="bibr" rid="CR4">4</xref></sup> Even when following these guidelines,
establishing a diagnosis can require iterative genetic testing. Previous expert
guidance on genetic testing for NDDs has advanced testing as standard of care for
individuals with NDDs.<sup><xref ref-type="bibr" rid="CR2">2</xref>,<xref ref-type="bibr" rid="CR5">5</xref></sup>
Such guidelines also predate the rapid uptake of clinical exome sequencing (ES) and
therefore ES is not addressed.</p>
<p id="Par6">Due to the genetic heterogeneity of NDDs, and the current standard of
genome-wide CMA as the first-tier test, we focused on ES in comparison with CMA
because it also provides a genome-wide assessment. The advent of ES has elucidated
monogenic forms of GDD/ID and/or ASD not detectable by CMA, FXS testing, or
single-gene sequencing of <italic>MECP2</italic> or <italic>PTEN</italic>.<sup><xref ref-type="bibr" rid="CR4">4</xref>,<xref ref-type="bibr" rid="CR6">6</xref></sup>
For individuals with GDD/ID, ASD, and/or multiple congenital anomalies (MCAs), the
molecular diagnostic yield of CMA is up to 15–20% (ref. <sup><xref ref-type="bibr" rid="CR5">5</xref></sup>), including more recent
cohorts.<sup><xref ref-type="bibr" rid="CR7">7</xref>–<xref ref-type="bibr" rid="CR9">9</xref></sup> CMA typically detects only chromosomal
copy-number variants (CNVs) and regions of homozygosity, not single-gene
disorders<sup><xref ref-type="bibr" rid="CR10">10</xref></sup> (Table <xref ref-type="table" rid="Tab1">1</xref>). Several ES studies have focused on individuals with varying
presentations of NDDs and have identified genetic causes in as many as 61% of
cases.<sup><xref ref-type="bibr" rid="CR1">1</xref>,<xref ref-type="bibr" rid="CR11">11</xref>,<xref ref-type="bibr" rid="CR12">12</xref></sup><table-wrap id="Tab1"><label>Table 1</label><caption><p>Types of genetic variants detected and missed by CMA and
ES</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Test</th><th>Types of variants detected</th><th>Types of variants missed</th></tr></thead><tbody><tr><td>CMA</td><td>Chromosomal copy-number variants (deletions and
duplications) at the level of intragenic exons or
larger</td><td><p>Balanced chromosomal rearrangements</p><p>Low-level mosaicism</p><p>Trinucleotide repeat expansion disorders (e.g.,
fragile X syndrome)</p><p>Single-gene sequence-level variants found by
ES</p></td></tr><tr><td>ES</td><td>Single-gene variants</td><td><p>Chromosomal copy-number variants (except when
specifically included in analysis pipeline)</p><p>Balanced chromosomal rearrangements</p><p>Trinucleotide repeat expansion
disorders</p><p>Intronic/noncoding variants</p><p>Exon-level deletions/duplications</p><p>Exonic variants not captured or covered well by
sequencing platform</p></td></tr></tbody></table><table-wrap-foot><p><italic>CMA</italic> chromosomal microarray,<italic>ES</italic> exome sequencing.</p></table-wrap-foot></table-wrap></p>
<p id="Par7">Much like CMA, ES is useful for patients with atypical presentations of
a genetic disorder, early presentations of a disease for which the classic findings
have not appeared, genetic disorders with relatively nonspecific presentations, and
multiple genetic conditions. One of the main historical limitations of ES was lack
of detection of CNVs (Table <xref ref-type="table" rid="Tab1">1</xref>), though
advances in depth-of-sequence coverage analysis and of apparent Mendelian
segregation errors can afford detection of CNVs from ES.<sup><xref ref-type="bibr" rid="CR13">13</xref></sup> With these advances, some
clinical laboratories have started to incorporate CNV analysis into their ES
platforms.</p>
<p id="Par8">The value of elucidating a molecular diagnosis is that it can change
clinical management in a number of important ways for individuals and families
affected by a NDD. Several studies have examined the impact of a diagnostic CMA
finding, showing that it leads to direct changes in patient care for up to 55% of
individuals with a positive result.<sup><xref ref-type="bibr" rid="CR14">14</xref>–<xref ref-type="bibr" rid="CR17">17</xref></sup> Similarly, a diagnosis via ES can impact patient
care by initiation of surveillance for disease-related conditions, discontinuation
of repeated rounds of investigation and irrelevant surveillance, and referrals for
further evaluation of associated medical conditions.<sup><xref ref-type="bibr" rid="CR18">18</xref></sup> Despite the clear benefit
of ES from a diagnostic and management standpoint, there are no accepted guidelines
for the use of ES in the evaluation of NDDs.</p>
<p id="Par9">Therefore, our primary objective was to conduct an evidence-based
consensus conference to provide recommendations for the use of ES in the diagnostic
evaluation of individuals with NDDs.</p>
</sec>
<sec id="Sec2" sec-type="materials|methods">
<title>MATERIALS AND METHODS</title>
<p id="Par10">We conducted a scoping review (no registered review protocol) as the
basis for a consensus development conference to summarize the molecular diagnostic
yield of ES for NDDs, specifically compared with CMA. For the conference, in
addition to the core group of experts who authored this paper, we also invited
outside experts on CNV analysis from ES data.</p>
<sec id="Sec3">
<title>Scoping review</title>
<p id="Par11">For this scoping review, we addressed the following question: Among
individuals with NDDs tested by ES, what is the molecular diagnostic yield
compared with CMA? We selected articles from PubMed focusing on ES and NDDs. We
included studies that involved sequencing of protein-coding regions of Mendelian
genes, and excluded studies that were gene panels subsampled from exome data. We
defined NDD as GDD, ID, and/or ASD. We searched PubMed with a combination of
Medical Subject Headings (MeSH) terms and keywords pertaining to NDDs (i.e.,
GDD, ID, and/or ASD) and ES, with dates from 1 January 2014 to 29 June 2018
(Table S<xref ref-type="media" rid="MOESM1">1</xref>). Scoping reviews differ
from systematic reviews in that their focus is on more broadly defined research
questions, charting of themes, and development of inclusion/exclusion criteria
at the study selection stage.<sup><xref ref-type="bibr" rid="CR19">19</xref></sup></p>
<p id="Par12">Article selection occurred in two stages. During the first stage,
12 expert reviewers (representing a diverse range of fields including laboratory
genetics, clinical genetics, genetic counseling, developmental behavioral
pediatrics, and medical students) were divided into dyads for determination of
possible inclusion. Articles included at this stage were primary research
studies (e.g., cohort studies, case series with ≥10 participants, review
articles, or other articles of interest such as expert opinion). Exclusion
criteria were as follows: the article did not (1) include the clinical
population of interest, (2) discuss ES, (3) include human data (e.g., an animal
or in vitro study only), (4) discuss molecular diagnostic yield, or (5) include
≥10 participants. Each dyad of reviewers was blinded to the other’s choices and
independently assigned inclusion/exclusion criteria for each article. When a
discrepancy occurred, an independent reviewer assessed whether the article
should advance to full article review.</p>
<p id="Par13">During the second stage, a dyad read the full text of each
remaining article for possible inclusion to clarify inclusion eligibility.
Reasons for exclusion at this stage were tiered by the following criteria: (1)
basic science study, (2) study population not exclusively NDD, (3) &lt;10
participants, (4) did not discuss ES, (5) no mention of molecular diagnostic
yield, (6) methods or review paper, or (7) not otherwise defined (book chapter
or not in English). We established strict phenotypic NDD guidelines to limit the
heterogeneity of included articles. Specifically, when describing the population
of interest, the article must have used the phrases “global developmental
delay,” “intellectual disability,” and/or “autism spectrum disorder” (or its
equivalent). The term “developmental delay” lacked enough specificity unless
there were additional context clues to suggest it was referring to GDD/ID. We
classified included articles as belonging to one of two categories: (1) isolated
NDD: the study population pertained to NDD; or (2) NDD plus associated
conditions: the study population pertained to NDD plus a specific clinical
finding (defined as <italic>any</italic> additional
neurological, systemic, syndromic, or other clinical characteristic, e.g.,
microcephaly, neutropenia, or Coffin–Siris syndrome).</p>
<p id="Par14">We conducted two iterative changes outside of the original scoping
review. First, during the conference, members nominated nine additional articles
for consideration. Select consensus conference members reviewed the articles’
full text and identified one additional article for inclusion that was not
ascertained through the MeSH and keyword search terms. Second, although our
manual review included “global developmental delay,” we modified our MeSH and
keyword search terms to include “global developmental delay” and to use “exome
sequencing” or “whole exome sequencing” (instead of just “whole exome
sequencing”). The same select consensus conference members reviewed all the
abstracts of the articles not previously captured by the initial MeSH and
keyword search terms, and read a subset of the full-text articles, ultimately
identifying one more article for inclusion.</p>
</sec>
<sec id="Sec4">
<title>Consensus development conference</title>
<p id="Par15">This effort began as an initiative of the Translational
Neuroscience Center (TNC) at Boston Children’s Hospital (BCH), following
multiple discussions with experts in the field. The idea of investigating
whether there was evidence to support use of clinical ES for patients with NDDs
was presented to a TNC donor who provided a modest noncommercial unrestricted
donation to support travel expenses of working group members to hold an
in-person meeting. The core author group from BCH then convened an
interdisciplinary group of experts in clinical genetics, laboratory genetics,
genetic counseling, child neurology, neurodevelopmental disabilities, and
developmental behavioral pediatrics to determine the need for a scoping review
on ES in NDDs. We conducted this project outside the scope of professional
organizations for two specific reasons: (1) we wanted the group of experts to
represent different countries and disciplines, to create diverse perspectives
that would minimize bias; and (2) we considered the question of selecting the
genetic test with highest diagnostic yield for NDDs to be an urgent issue, and
that our approach would be expedient without compromising the validity of
conclusions.</p>
<p id="Par16">This consensus group developed the framework and selected separate
experts to conduct the review. Members of the consensus group provided conflicts
of interest disclosure in a standard format. Following the scoping review, the
consensus group reconvened to review the evidence curated by the expert review
group. We assembled this interdisciplinary team based on practice/geographic
diversity and assessments of conflicts of interest, and we used a consensus
development conference approach.<sup><xref ref-type="bibr" rid="CR20">20</xref></sup> This approach is one of the three main
approaches to develop consensus and was chosen for its unique strength of
allowing committee members a forum to discuss issues.<sup><xref ref-type="bibr" rid="CR21">21</xref></sup> The committee reviewed
the evidence table, discussed talks on relevant topics presented by a variety of
members and two external experts from clinical laboratories performing ES, voted
on the use of ES as a first-tier test for NDDs, and developed a consensus
algorithm for genetic testing, including ES, in NDDs.</p>
</sec>
<sec id="Sec5">
<title>Statistical analysis</title>
<p id="Par17">We assessed fixed-effects and random-effects models for model fit.
We performed a random-effects meta-regression to determine molecular diagnostic
yield of full sample, and stratified by category (isolated NDD, NDD plus
associated conditions). Category, year of study, number of participants with a
NDD, and number of family members included per proband were evaluated as
covariates. For number of family members included, we created three categories:
(1) proband-only (all cases proband-only), (2) combination (all cases <italic>at least</italic> proband), and (3) trio (all cases<italic>at least</italic> trios). Of note, we included two
studies in the combination category in which parental samples were obtained post
hoc for variant classification.</p>
<p id="Par18">Meta-regression was performed using a logistic regression model.
Between-study heterogeneity was assessed using between-study variance
(τ<sup>2</sup>), I-2 statistic, and Cochran’s Q-test. Akaike
information criterion and Bayesian information criterion were assessed to
evaluate model fit. A forest plot was used to summarize our findings.</p>
</sec>
</sec>
<sec id="Sec6" sec-type="results">
<title>RESULTS</title>
<p id="Par19">For the scoping review staged selection process, we initially
identified 584 unique articles. We eliminated 464 articles after abstract review,
and another 92 after full-text review, leaving 28 articles for inclusion. During the
iterative review, we identified 389 unique articles, eliminated 378 after abstract
review, and another 9 after full-text review, leaving 2 for inclusion. In total, 30
articles were included, which we divided into two categories: those focused on just
NDDs or those focused on NDDs plus associated conditions. Preferred Reporting Items
for Systematic Reviews and Meta-Analyses (PRISMA) flowchart is shown in
Fig. <xref ref-type="fig" rid="Fig1">1</xref>.<fig id="Fig1"><label>Fig. 1</label><caption><p><bold>Preferred Reporting Items for
Systematic Reviews and Meta-Analyses (PRISMA) flowchart of
scoping review article inclusion.</bold>
<sup>a</sup>Records identified through iterative
review were reviewed by one reviewer at the screening stage.<italic>ES</italic> exome sequencing,<italic>NDD</italic> neurodevelopmental
disorder.</p></caption><graphic id="d30e892" xlink:href="41436_2019_554_Fig1_HTML"></graphic></fig></p>
<p id="Par20">The 30 articles (Table S<xref ref-type="media" rid="MOESM2">2</xref>)
were diverse in their patient representations. These articles originated from
centers around the world, including the United States, Europe, Middle East, and
Asia. Among the articles focused on NDD plus associated conditions, the features
included features of a clinically defined syndrome (e.g., Coffin–Siris syndrome,
DOOR syndrome, Nicolaides–Baraitser syndromes, Rett syndrome, Smith–Magenis
syndrome); systemic findings (unexplained metabolic phenotype); associated medical
problems (neutropenia); and neurological features (microcephaly, macrocephaly). The
types of specialists evaluating the phenotypes of participants represented a diverse
variety including clinical geneticists, pediatric neurologists, and developmental
pediatricians.</p>
<p id="Par21">A random-effects meta-analysis of the 30 articles revealed a molecular
diagnostic yield of ES of 36% (confidence interval [CI]: 30–43%) weighted by the
number of cases in the study (Fig. <xref ref-type="fig" rid="Fig2">2</xref>). In
the isolated NDD category (<italic>n</italic> = 21 articles), the
yield was 31% (CI: 25–38%), and in the NDD plus associated conditions category
(<italic>n</italic> = 9 articles), the yield was 53% (CI:
41–64%).<fig id="Fig2"><label>Fig. 2</label><caption><p><bold>Forest plot of meta-analysis
subcategorized as neurodevelopmental disorder (NDD) and NDD plus
associated conditions.</bold><italic>CI</italic> confidence
interval.</p></caption><graphic id="d30e921" xlink:href="41436_2019_554_Fig2_HTML"></graphic></fig></p>
<p id="Par22">Within both the isolated NDD category and the NDD plus associated
conditions category, patterns emerged pertaining to molecular diagnostic yield.
Among the articles pertaining to the isolated NDD category, there were <italic>n</italic> = 5 articles including individuals with primarily ASD
(molecular diagnostic yield 16%, CI: 11–24%), <italic>n</italic> = 10 articles that included individuals with primarily ID (yield 39%,
CI: 29–50%), <italic>n</italic> = 6 articles that included
individuals with a more heterogeneous mix of ID and/or ASD (yield: 39% (CI:
29%–50%)), and <italic>n</italic> = 4 articles focused on mostly
consanguineous populations (yield: 29%, CI: 23–35%). Meta-regression revealed that
year of study, number of family members sequenced, and isolated NDD versus NDD plus
associated conditions category did not significantly predict molecular diagnostic
yield.</p>
<p id="Par23">Several studies (<italic>n</italic> = 6) showed that
a presumptive diagnosis by ES could change clinical management (Table S<xref ref-type="media" rid="MOESM2">2</xref>). Among those with a diagnosis by ES, changes in
medical/medication management occurred in 30% (range: 2–46%; <italic>n</italic> = 6 studies). Four studies discussed impact on reproductive
planning and found that 80% (range: 42–100%) of diagnoses were informative for
reproductive planning. For those for whom the diagnosis was not informative for
reproductive planning, the reasons were not entirely clear. Of note, these numbers
on clinical management impact are not necessarily specific to individuals with NDD,
since for some studies, we used a subset of the study population to calculate
molecular diagnostic yield for NDDs.</p>
</sec>
<sec id="Sec7" sec-type="discussion">
<title>DISCUSSION</title>
<p id="Par24">Our scoping review revealed that, among patients with NDDs, ES
outperforms the currently accepted first-tier test for NDDs by 10–28%, assuming a
range of 30–43% for ES and 15–20% for CMA. Both of these tests are advantageous as
unbiased approaches with genetically heterogeneous conditions like NDDs. However,
based on this significantly higher molecular diagnostic yield combined with the fact
that a diagnosis often impacts clinical management, we recommend ES (including both
parents, when feasible and with multiple affected family member analysis, when
indicated) as a first-tier test for individuals with unexplained NDDs
(Fig. <xref ref-type="fig" rid="Fig3">3</xref>). In fact, ES has advantages,
such as detection of individuals with multiple monogenic disorders, facilitating
characterization of blended phenotypes.<sup><xref ref-type="bibr" rid="CR22">22</xref></sup> Multiple prior studies have shown that
results from ES impact clinical management for NDDs and other
conditions,<sup><xref ref-type="bibr" rid="CR18">18</xref>,<xref ref-type="bibr" rid="CR23">23</xref></sup> which our results support.<fig id="Fig3"><label>Fig. 3</label><caption><p><bold>Diagnostic algorithm incorporating
exome sequencing (ES) in the clinical evaluation of individuals
with unexplained neurodevelopmental disorders (NDDs) (global
developmental delay/intellectual disability [GDD/ID] and/or
autism spectrum disorder [ASD]).</bold> An incomplete
diagnosis represents a diagnosis that explains only part of an
individual’s phenotype. Factors such as the turnaround time of test,
availability of tests, and availability of genetic counseling may be
considerations in application of this algorithm in clinical use.
<sup>a</sup>Or technology that supersedes ES
such as genome sequencing. <italic>CMA</italic>
chromosomal microarray, <italic>CNV</italic>
copy-number variant.</p></caption><graphic id="d30e985" xlink:href="41436_2019_554_Fig3_HTML"></graphic></fig></p>
<p id="Par25">If ES is nondiagnostic, we suggest that the next step in the evaluation
is CMA (if not already performed, either standalone or as part of ES analysis). If
CMA is nondiagnostic, then the clinician can consider further evaluations/tests,
including, but not limited to, referral to a clinical geneticist for expert
evaluation; periodic (every 1–3 years) reanalysis of ES data, given evidence that
doing so may enhance molecular diagnostic yield by 10–16% (refs.
<sup><xref ref-type="bibr" rid="CR24">24</xref>–<xref ref-type="bibr" rid="CR26">26</xref></sup>); FXS testing; metabolic testing and/or
mitochondrial DNA (mtDNA) sequencing based on clinical presentation (though some
laboratories perform mtDNA analysis with ES); and karyotyping to assess for balanced
chromosomal rearrangements.</p>
<p id="Par26">Our algorithm places ES before, or concurrent with, CMA, as the
molecular diagnostic yield of ES for NDDs exceeds that of CMA. Estimates for the
molecular diagnostic yield of CMA are 15–20%, but this number includes individuals
with MCAs, which we did not include in our inclusion criteria unless there was also
the presence of GDD/ID and/or ASD. There are certain additional points that will
allow this algorithm to remain meaningful as sequencing technology and bioinformatic
analyses continue to improve. First, CNV analysis is typically not a standard
application of ES across all labs. As a result, the diagnostic yield of CMA and ES
for NDDs is approximately the sum of each respective diagnostic yield (i.e., 15–20%
for CMA based on prior literature plus 30–43% for ES in our study). Nonetheless,
there is increasing movement toward incorporating CNV calling algorithms into ES
analysis pipelines.<sup><xref ref-type="bibr" rid="CR27">27</xref></sup> For example, within the articles included in our
scoping review, three studies called CNVs from exome:<sup><xref ref-type="bibr" rid="CR1">1</xref>,<xref ref-type="bibr" rid="CR28">28</xref>,<xref ref-type="bibr" rid="CR29">29</xref></sup> two reported CNV yields for NDDs of 16.7% (ref.
<sup><xref ref-type="bibr" rid="CR28">28</xref></sup>)
and 6.4% (ref. <sup><xref ref-type="bibr" rid="CR29">29</xref></sup>), and the latter identified two pathogenic CNVs
that were not detected on CMA due to poor coverage.<sup><xref ref-type="bibr" rid="CR29">29</xref></sup> Second, genome sequencing
(GS), by definition, captures more comprehensively all classes of genetic variants
in testing (Table <xref ref-type="table" rid="Tab1">1</xref>). We anticipate that GS
will eventually supersede ES and CMA in clinical testing algorithms over time, as
cost decreases.</p>
<p id="Par27">It is worthwhile to note comparisons between ES and panel testing.
Sensitivity for detection of mosaicism can be lower on ES compared with panel
testing, for which read depth and sequence coverage is often
greater.<sup><xref ref-type="bibr" rid="CR30">30</xref></sup> ES has lower sensitivity to detect single
exon–level deletions/duplications, which may be better detected by panels when
targeted deletion/duplication analysis is included. However, gene panels require
continual curation of a well-defined/comprehensive gene set for phenotypes for which
many genes are yet to be discovered.<sup><xref ref-type="bibr" rid="CR31">31</xref></sup> Moreover, panels are fixed in the number of
genes originally assessed, while ES allows for reanalysis of the data set.</p>
<p id="Par28">It is also important to note that a diagnosis from ES should not end
with laboratory classification of a variant. For instance, the classification of a
variant of unknown significance (VUS) from a laboratory should be further evaluated
in the clinical setting. With increased knowledge over time of phenotypes related to
different genetic disorders, exome reanalysis may change the clinical interpretation
of a VUS. Furthermore, a likely pathogenic variant has approximately a 90% true
positive rate, so there is approximately a 10% false positive rate as the cause of
an individual’s presentation; therefore, clinical judgment is important in
establishing a diagnosis.<sup><xref ref-type="bibr" rid="CR32">32</xref></sup> Even pathogenic variants may be incompletely
penetrant or only partly explain presenting features. Ultimately, final variant
interpretation of the ES test result requires review by expert clinicians who can
reassess the patient’s phenotype in light of the suggested molecular
diagnosis.</p>
<p id="Par29">Our results demonstrate that the presence of additional clinical
features, year of study, and number of family members included in exome analysis did
not correlate with molecular diagnostic yield in our meta-regression. Factors such
as number of studies pertaining to each of the variables may have contributed to
this result, and therefore it still may be the case that the presence of multiple
additional phenotypic features may enrich molecular diagnostic yield (as evidenced
by the fact there was a higher diagnostic yield in the NDD plus associated
conditions category versus the isolated NDD category, though not statistically
significant). Additionally, while our findings did not demonstrate higher yield when
including more family members, many of the studies were a mixture of proband-only
and trio ES, limiting our ability to detect differences in molecular diagnostic
yield. Because of this, we expect that the additional yield of trio ES seen in other
studies remains true.<sup><xref ref-type="bibr" rid="CR1">1</xref>,<xref ref-type="bibr" rid="CR33">33</xref></sup> Our analysis did not account for history of
consanguinity in the meta-regression, though this additional factor may enrich
molecular diagnostic yield, based on increased probability of autosomal recessive
conditions. Additionally, we were not able to determine whether increased ID
severity increased molecular diagnostic yield in our regression, but this factor may
be another consideration. In sum, ES demonstrates a higher diagnostic yield,
relative to CMA, for individuals with NDDs, with/without additional features. This
is attributable to the ability of ES to detect the most prevalent types of
pathogenic variants affecting this population (single-nucleotide variants [SNVs]),
and that those SNVs represent many loci. This is not surprising because the
phenotypic category of NDDs features a high degree of locus heterogeneity and
phenotypic variability.</p>
<p id="Par30">It is worthwhile to consider who would order ES as a first-line test
for NDDs. We suggest that test ordering should not be limited to a particular
specialty; rather, it is contingent on the ordering provider’s ability to provide
informed consent about variant interpretation and secondary findings, and the
ability to interpret/report results. Providers should inform patients on possible
results, both primary and secondary.<sup><xref ref-type="bibr" rid="CR34">34</xref></sup> We have not included assessments of
cost-effectiveness and insurance approval for ES in our evaluation.</p>
<p id="Par31">Laboratory interpretation standards, case review boards, and reanalysis
protocols might also affect yield from exome sequencing.<sup><xref ref-type="bibr" rid="CR24">24</xref>,<xref ref-type="bibr" rid="CR26">26</xref>,<xref ref-type="bibr" rid="CR35">35</xref></sup> We compared diagnostic yield of ES to CMA, and
note that CMA results can also be affected in the same
ways.<sup><xref ref-type="bibr" rid="CR36">36</xref></sup> A recent prospective study examined the use of
ES for establishing molecular diagnoses in fetal structural anomalies, involving
multidisciplinary input that is important when the phenotype is
complex.<sup><xref ref-type="bibr" rid="CR37">37</xref></sup></p>
<p id="Par32">Our analysis had limitations. The scoping review focused on ID and/or
ASD, since these are the two NDDs for which there are recommendations already in
place for genetic testing. We recognize that our search strategy may have led to
exclusion of some articles where phenotype was less specific, such as use of
“developmental delay” instead of GDD. For reasons of consistency, we were stricter
in our search strategy. Second, we made inferences about the study population in<italic>n</italic> = 9 studies (e.g., presuming “ID/DD” is
ID/GDD). Several studies did not formally define the basis for ASD or ID/GDD. Even
in studies belonging to the isolated NDD group, the study population was
heterogeneous (e.g., ID plus variable other features though not necessarily plus
another specific phenotype). Moreover, although our scoping review had selected
articles focusing on GDD, it had not been included in our initial MeSH terms, so we
repeated our PubMed search with this change. Further, we excluded certain studies
with heterogeneous cohorts for which we could not ascertain the number of
individuals with NDD. One such study focused on ID <italic>and/or</italic> epileptic encephalopathies,<sup><xref ref-type="bibr" rid="CR38">38</xref></sup> while another such study
focused on NDDs (but broadly defined NDD to include a heterogeneous array of
neurological symptoms without clear delineation of subset with GDD/ID and/or
ASD).<sup><xref ref-type="bibr" rid="CR39">39</xref></sup> Though it may seem surprising that there were
more papers on isolated NDD than NDD plus associated conditions, the reason for this
is that we only included an article in the NDD plus associated conditions category
if <italic>all</italic> participants in that article had NDDs on
top of the additional feature(s). In addition, not all studies used the ACMG variant
classification guidelines. In part, this was due to the time period of study
inclusion, which began in 2014; the ACMG did not release variant classification
guidelines until 2015.<sup><xref ref-type="bibr" rid="CR40">40</xref></sup> Another limitation is that we did not include
mtDNA sequencing in our analysis. We also recognize that the data were drawn from a
variety of both clinical and research settings, and that specific analysis
approaches may differ in terms of variant filtering and technical platform (e.g,
trio-based ES versus proband-only ES). It is expected that by looking at
meta-analysis we account for some of this variability. The second to last limitation
is that we acknowledge additional cost analyses associated with the genetic testing
technologies will also be important, though these were not part of the original
purpose of our study, which focused on molecular diagnostic yield. Finally, while
there may be publication bias favoring positive results, this effect is diminished
by the large cohorts in our analysis and multiple studies involving consecutively
ascertained cases. Publication bias should apply equally to studies on yield of CMA
and ES.</p>
<p id="Par33">Our work establishes that, among patients with NDD, ES produces a
higher molecular diagnostic yield than CMA, so by this criterion and as outlined in
our algorithm (Fig. <xref ref-type="fig" rid="Fig3">3</xref>), it should become a
first-tier test. As our recommended algorithm is adopted, we anticipate numerous
additional health and economic impact studies about changes in patient-related
outcomes enabled by genome sequence–based diagnosis. While step-wise testing has
historically had a role in identifying a genetic diagnosis, simplicity is ideal, and
a diagnosis can now be accomplished for many patients in a single test with an
already impressively high molecular diagnostic yield. Such clinical diagnostic
yields will increase with reannotation of the existing data compared with new data
sets and with new computational tools.<sup><xref ref-type="bibr" rid="CR32">32</xref></sup> This report will guide geneticists,
neurologists, developmental pediatricians, child psychiatrists, and other clinicians
in incorporating clinical exome or genome sequencing into the management of
individuals with NDDs.</p>
</sec>
<sec sec-type="supplementary-material">
<title>Supplementary information</title>
<sec id="Sec8">
<p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="41436_2019_554_MOESM1_ESM.docx"><caption><p>Supplementary TableS1</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM2"><media xlink:href="41436_2019_554_MOESM2_ESM.xlsx"><caption><p>Supplementary TableS2</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM3"><media xlink:href="41436_2019_554_MOESM3_ESM.xlsx"><caption><p>Supplementary Table</p></caption></media></supplementary-material>
</p>
</sec>
</sec>
</body>
<back>
<fn-group>
<fn>
<p><bold>Publisher’s note:</bold> Springer Nature remains
neutral with regard to jurisdictional claims in published maps and institutional
affiliations.</p>
</fn>
<fn>
<p>These authors contributed equally: Siddharth Srivastava, Jamie A.
Love-Nichols.</p>
</fn>
<fn>
<p>
<bold>Change history</bold>
</p>
<p>7/29/2020</p>
<p>In our meta-analysis, we utilized incorrect numbers of individuals for one
publication (Retterer et al., 2016) due to the fact the numbers for ASD and
ID groups were not independent representations. We have updated our analysis
using corrected numbers based on correspondence with the first author of
this paper (diagnostic yield for NDD = 543/1736 as opposed to 570/2063). The
updated analysis leads to the same (rounded) weighted diagnostic yield and
confidence intervals (CI) as the initial publication (36% [30%–43%]). The
updated analysis results in the following updated values in Figure 2 --
Retterer study values: N positive = 543, N total = 1736, study weight = 5.3%
and meta-analysis statistics: I2 = 80%, t2 = 0.2835, <italic>p</italic> &lt; 0.01. The study is also included in two subanalyses
reported in the Results. The isolated NDD subcategory (<italic>n</italic> = 21 articles), updated analysis leads to
same (rounded) weighted diagnostic yield and confidence intervals as
published (31% [25%–38%]). For the sub-analysis of mix of ID and/or ASD, the
initial yield was 37% (CI: 29%–46%). Following updated analysis, the yield
of this subset is 39% (CI: 29%–50%).</p>
</fn>
</fn-group>
<sec>
<title>Supplementary information</title>
<p>The online version of this article (10.1038/s41436-019-0554-6) contains supplementary material, which is available to authorized
users.</p>
</sec>
<ack>
<title>Acknowledgements</title>
<p>The authors acknowledge members of the Exome Scoping Review Work Group
participating in the literature scoping review: Bibiana Restrepo and Suma Shankar
(MIND Institute, Department of Pediatrics, University of California Davis), Erin
Rooney Riggs (Autism &amp; Developmental Medicine Institute, Geisinger), Pete
Constantinou (West of Scotland Regional Genetics Service, Glasgow, UK), Anne
Reed-Weston (Columbia University College of Physicians &amp; Surgeons), R. Spencer
Tong (The Hospital for Sick Children), Jennifer Howe and Janet Buchanan (The
Hospital for Sick Children), Rachel Fisher (University of Michigan), and Sonal
Mahida (Epilepsy Genetics, Boston Children’s Hospital [BCH]). We also acknowledge
the Wade Family Foundation for their financial support of the consensus conference,
Caterina Stamoulis (Departments of Medicine and Neurology, BCH) for review of
statistical methodology, and librarian Meaghan Muir (BCH) for PubMed and scoping
review methodology guidance.</p>
</ack>
<notes id="FPar1" notes-type="COI-statement">
<title>Disclosure</title>
<p id="Par34">All authors completed the International Committee of Medical
Journal Editors conflict of interest disclosure forms, which were reviewed by
the senior authors. H.V.F. reports personal fees from UpToDate, outside the
submitted work. T.F. has received federal funding or research support from,
acted as a consultant to, received travel support from, and/or received a
speaker's honorarium from the Cole Family Research Fund, Simons Foundation,
Ingalls Foundation, Forest Laboratories, Ecoeos, IntegraGen, Kugona LLC, Shire
Development, Bristol-Myers Squibb, Roche Pharma, National Institutes of Health,
and the Brain and Behavior Research Foundation, all unrelated to this project.
S.W.S. is on the Scientific Advisory Committees of Population Bio and Deep
Genomics, and intellectual property from his research held at the Hospital for
Sick Children is licensed to Athena Diagnostics, and separately Lineagen. These
relationships did not influence data interpretation or presentation during this
study, but are being disclosed for potential future considerations. M.S. reports
grant support from Novartis, Roche, Pfizer, Ipsen, LAM Therapeutics and Quadrant
Biosciences, and he has served on Scientific Advisory Boards for Sage, Roche,
Celgene, and Takeda, all unrelated to this project. The other authors declare no
conflicts of interest.</p>
</notes>
<ref-list id="Bib1">
<title>References</title>
<ref id="CR1">
<label>1.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Retterer</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Juusola</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Cho</surname>
<given-names>MT</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Clinical application of whole-exome sequencing
across clinical indications</article-title>
<source/>Genet Med
          <year>2016</year>
<volume>18</volume>
<fpage>696</fpage>
<lpage>704</lpage>
<pub-id pub-id-type="pmid">26633542</pub-id>
</element-citation>
</ref>
<ref id="CR2">
<label>2.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schaefer</surname>
<given-names>GB</given-names>
</name>
<name>
<surname>Mendelsohn</surname>
<given-names>NJ</given-names>
</name>
<collab>Professional Practice and Guidelines
Committee.</collab>
</person-group>
<article-title>Clinical genetics evaluation in identifying the
etiology of autism spectrum disorders: 2013 guideline
revisions</article-title>
<source/>Genet Med
          <year>2013</year>
<volume>15</volume>
<fpage>399</fpage>
<lpage>407</lpage>
<pub-id pub-id-type="pmid">23519317</pub-id>
</element-citation>
</ref>
<ref id="CR3">
<label>3.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Manning</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Hudgins</surname>
<given-names>L</given-names>
</name>
<collab>Professional Practice and Guidelines
Committee.</collab>
</person-group>
<article-title>Array-based technology and recommendations for
utilization in medical genetics practice for detection of chromosomal
abnormalities</article-title>
<source/>Genet Med
          <year>2010</year>
<volume>12</volume>
<fpage>742</fpage>
<lpage>745</lpage>
<pub-id pub-id-type="pmid">20962661</pub-id>
</element-citation>
</ref>
<ref id="CR4">
<label>4.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vissers</surname>
<given-names>LELM</given-names>
</name>
<name>
<surname>Gilissen</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Veltman</surname>
<given-names>JA</given-names>
</name>
</person-group>
<article-title>Genetic studies in intellectual disability and
related disorders</article-title>
<source/>Nat Rev Genet
          <year>2016</year>
<volume>17</volume>
<fpage>9</fpage>
<lpage>18</lpage>
<pub-id pub-id-type="pmid">26503795</pub-id>
</element-citation>
</ref>
<ref id="CR5">
<label>5.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Miller</surname>
<given-names>DT</given-names>
</name>
<name>
<surname>Adam</surname>
<given-names>MP</given-names>
</name>
<name>
<surname>Aradhya</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Consensus statement: chromosomal microarray is a
first-tier clinical diagnostic test for individuals with developmental
disabilities or congenital anomalies</article-title>
<source/>Am J Hum Genet
          <year>2010</year>
<volume>86</volume>
<fpage>749</fpage>
<lpage>764</lpage>
<pub-id pub-id-type="pmid">20466091</pub-id>
</element-citation>
</ref>
<ref id="CR6">
<label>6.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vorstman</surname>
<given-names>JAS</given-names>
</name>
<name>
<surname>Parr</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Moreno-De-Luca</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Anney</surname>
<given-names>RJL</given-names>
</name>
<name>
<surname>Nurnberger</surname>
<given-names>JI</given-names>
</name>
<name>
<surname>Hallmayer</surname>
<given-names>JF</given-names>
</name>
</person-group>
<article-title>Autism genetics: opportunities and challenges for
clinical translation</article-title>
<source/>Nat Rev Genet
          <year>2017</year>
<volume>18</volume>
<fpage>362</fpage>
<lpage>376</lpage>
<pub-id pub-id-type="pmid">28260791</pub-id>
</element-citation>
</ref>
<ref id="CR7">
<label>7.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jang</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>E</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Chromosomal microarray analysis as a first-tier
clinical diagnostic test in patients with developmental delay/intellectual
disability, autism spectrum disorders, and multiple congenital anomalies: a
prospective multicenter study in Korea</article-title>
<source/>Ann Lab Med
          <year>2019</year>
<volume>39</volume>
<fpage>299</fpage>
<lpage>310</lpage>
<pub-id pub-id-type="pmid">30623622</pub-id>
</element-citation>
</ref>
<ref id="CR8">
<label>8.</label>
<mixed-citation publication-type="other">Cheng SSW, Chan KYK, Leung KKP, et al. Experience of chromosomal
microarray applied in prenatal and postnatal settings in Hong Kong. Am J Med
Genet C Semin Med Genet. 2019 Mar 23; doi:10.1002/ajmg.c.31697 [Epub ahead of
print].</mixed-citation>
</ref>
<ref id="CR9">
<label>9.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Battaglia</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Doccini</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Bernardini</surname>
<given-names>L</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Confirmation of chromosomal microarray as a
first-tier clinical diagnostic test for individuals with developmental
delay, intellectual disability, autism spectrum disorders and dysmorphic
features</article-title>
<source/>Eur J Paediatr Neurol
          <year>2013</year>
<volume>17</volume>
<fpage>589</fpage>
<lpage>599</lpage>
<pub-id pub-id-type="pmid">23711909</pub-id>
</element-citation>
</ref>
<ref id="CR10">
<label>10.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Waggoner</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Wain</surname>
<given-names>KE</given-names>
</name>
<name>
<surname>Dubuc</surname>
<given-names>AM</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Yield of additional genetic testing after
chromosomal microarray for diagnosis of neurodevelopmental disability and
congenital anomalies: a clinical practice resource of the American College
of Medical Genetics and Genomics (ACMG)</article-title>
<source/>Genet Med
          <year>2018</year>
<volume>20</volume>
<fpage>1105</fpage>
<lpage>1113</lpage>
<pub-id pub-id-type="pmid">29915380</pub-id>
</element-citation>
</ref>
<ref id="CR11">
<label>11.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xiao</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Qiu</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Ji</surname>
<given-names>X</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Marked yield of re-evaluating phenotype and
exome/target sequencing data in 33 individuals with intellectual
disabilities</article-title>
<source/>Am J Med Genet A
          <year>2018</year>
<volume>176</volume>
<fpage>107</fpage>
<lpage>115</lpage>
<pub-id pub-id-type="pmid">29159939</pub-id>
</element-citation>
</ref>
<ref id="CR12">
<label>12.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Loviglio</surname>
<given-names>MN</given-names>
</name>
<name>
<surname>Beck</surname>
<given-names>CR</given-names>
</name>
<name>
<surname>White</surname>
<given-names>JJ</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Identification of a RAI1-associated disease network
through integration of exome sequencing, transcriptomics, and 3D
genomics</article-title>
<source/>Genome Med
          <year>2016</year>
<volume>8</volume>
<fpage>105</fpage>
<pub-id pub-id-type="pmid">27799067</pub-id>
</element-citation>
</ref>
<ref id="CR13">
<label>13.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pfundt</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Del Rosario</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Vissers</surname>
<given-names>LELM</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Detection of clinically relevant copy-number
variants by exome sequencing in a large cohort of genetic
disorders</article-title>
<source/>Genet Med
          <year>2017</year>
<volume>19</volume>
<fpage>667</fpage>
<lpage>675</lpage>
<pub-id pub-id-type="pmid">28574513</pub-id>
</element-citation>
</ref>
<ref id="CR14">
<label>14.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Coulter</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>DT</given-names>
</name>
<name>
<surname>Harris</surname>
<given-names>DJ</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Chromosomal microarray testing influences medical
management</article-title>
<source/>Genet Med
          <year>2011</year>
<volume>13</volume>
<fpage>770</fpage>
<lpage>776</lpage>
<pub-id pub-id-type="pmid">21716121</pub-id>
</element-citation>
</ref>
<ref id="CR15">
<label>15.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ellison</surname>
<given-names>JW</given-names>
</name>
<name>
<surname>Ravnan</surname>
<given-names>JB</given-names>
</name>
<name>
<surname>Rosenfeld</surname>
<given-names>JA</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Clinical utility of chromosomal microarray
analysis</article-title>
<source/>Pediatrics
          <year>2012</year>
<volume>130</volume>
<fpage>e1085</fpage>
<lpage>1095</lpage>
<pub-id pub-id-type="pmid">23071206</pub-id>
</element-citation>
</ref>
<ref id="CR16">
<label>16.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Riggs</surname>
<given-names>ER</given-names>
</name>
<name>
<surname>Wain</surname>
<given-names>KE</given-names>
</name>
<name>
<surname>Riethmaier</surname>
<given-names>D</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Chromosomal microarray impacts clinical
management</article-title>
<source/>Clin Genet
          <year>2014</year>
<volume>85</volume>
<fpage>147</fpage>
<lpage>153</lpage>
<pub-id pub-id-type="pmid">23347240</pub-id>
</element-citation>
</ref>
<ref id="CR17">
<label>17.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Henderson</surname>
<given-names>LB</given-names>
</name>
<name>
<surname>Applegate</surname>
<given-names>CD</given-names>
</name>
<name>
<surname>Wohler</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Sheridan</surname>
<given-names>MB</given-names>
</name>
<name>
<surname>Hoover-Fong</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Batista</surname>
<given-names>DAS</given-names>
</name>
</person-group>
<article-title>The impact of chromosomal microarray on clinical
management: a retrospective analysis</article-title>
<source/>Genet Med
          <year>2014</year>
<volume>16</volume>
<fpage>657</fpage>
<lpage>664</lpage>
<pub-id pub-id-type="pmid">24625444</pub-id>
</element-citation>
</ref>
<ref id="CR18">
<label>18.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tan</surname>
<given-names>TY</given-names>
</name>
<name>
<surname>Dillon</surname>
<given-names>OJ</given-names>
</name>
<name>
<surname>Stark</surname>
<given-names>Z</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Diagnostic impact and cost-effectiveness of
whole-exome sequencing for ambulant children with suspected monogenic
conditions</article-title>
<source/>JAMA Pediatr
          <year>2017</year>
<volume>171</volume>
<fpage>855</fpage>
<lpage>862</lpage>
<pub-id pub-id-type="pmid">28759686</pub-id>
</element-citation>
</ref>
<ref id="CR19">
<label>19.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Colquhoun</surname>
<given-names>HL</given-names>
</name>
<name>
<surname>Levac</surname>
<given-names>D</given-names>
</name>
<name>
<surname>O’Brien</surname>
<given-names>KK</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Scoping reviews: time for clarity in definition,
methods, and reporting</article-title>
<source/>J Clin Epidemiol
          <year>2014</year>
<volume>67</volume>
<fpage>1291</fpage>
<lpage>1294</lpage>
<pub-id pub-id-type="pmid">25034198</pub-id>
</element-citation>
</ref>
<ref id="CR20">
<label>20.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fink</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kosecoff</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Chassin</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Brook</surname>
<given-names>RH</given-names>
</name>
</person-group>
<article-title>Consensus methods: characteristics and guidelines
for use</article-title>
<source/>Am J Public Health
          <year>1984</year>
<volume>74</volume>
<fpage>979</fpage>
<lpage>983</lpage>
<pub-id pub-id-type="pmid">6380323</pub-id>
</element-citation>
</ref>
<ref id="CR21">
<label>21.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Murphy</surname>
<given-names>MK</given-names>
</name>
<name>
<surname>Black</surname>
<given-names>NA</given-names>
</name>
<name>
<surname>Lamping</surname>
<given-names>DL</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Consensus development methods, and their use in
clinical guideline development</article-title>
<source/>Health Technol Assess
          <year>1998</year>
<volume>2</volume>
<fpage>i-iv</fpage>
<lpage>1-88</lpage>
</element-citation>
</ref>
<ref id="CR22">
<label>22.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>O’Donnell-Luria</surname>
<given-names>AH</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>DT</given-names>
</name>
</person-group>
<article-title>A clinician’s perspective on clinical exome
sequencing</article-title>
<source/>Hum Genet
          <year>2016</year>
<volume>135</volume>
<fpage>643</fpage>
<lpage>654</lpage>
<pub-id pub-id-type="pmid">27126233</pub-id>
</element-citation>
</ref>
<ref id="CR23">
<label>23.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dixon-Salazar</surname>
<given-names>TJ</given-names>
</name>
<name>
<surname>Silhavy</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Udpa</surname>
<given-names>N</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Exome sequencing can improve diagnosis and alter
patient management</article-title>
<source/>Sci Transl Med
          <year>2012</year>
<volume>4</volume>
<fpage>138ra78</fpage>
<pub-id pub-id-type="pmid">22700954</pub-id>
</element-citation>
</ref>
<ref id="CR24">
<label>24.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wenger</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Guturu</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Bernstein</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Bejerano</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>Systematic reanalysis of clinical exome data yields
additional diagnoses: implications for providers</article-title>
<source/>Genet Med
          <year>2017</year>
<volume>19</volume>
<fpage>209</fpage>
<lpage>214</lpage>
<pub-id pub-id-type="pmid">27441994</pub-id>
</element-citation>
</ref>
<ref id="CR25">
<label>25.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Al-Nabhani</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Al-Rashdi</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Al-Murshedi</surname>
<given-names>F</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Reanalysis of exome sequencing data of intellectual
disability samples: yields and benefits</article-title>
<source/>Clin Genet
          <year>2018</year>
<volume>94</volume>
<fpage>495</fpage>
<lpage>501</lpage>
<pub-id pub-id-type="pmid">30125339</pub-id>
</element-citation>
</ref>
<ref id="CR26">
<label>26.</label>
<mixed-citation publication-type="other">Salmon LB, Orenstein N, Markus-Bustani K, et al. Improved
diagnostics by exome sequencing following raw data reevaluation by clinical
geneticists involved in the medical care of the individuals tested. Genet Med.
2018 Oct 31; doi:10.1038/s41436-018-0343-7 [Epub ahead of
print].</mixed-citation>
</ref>
<ref id="CR27">
<label>27.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Retterer</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Scuffins</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Schmidt</surname>
<given-names>D</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Assessing copy number from exome sequencing and
exome array CGH based on CNV spectrum in a large clinical
cohort</article-title>
<source/>Genet Med
          <year>2015</year>
<volume>17</volume>
<fpage>623</fpage>
<lpage>629</lpage>
<pub-id pub-id-type="pmid">25356966</pub-id>
</element-citation>
</ref>
<ref id="CR28">
<label>28.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Charng</surname>
<given-names>W-L</given-names>
</name>
<name>
<surname>Karaca</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Coban Akdemir</surname>
<given-names>Z</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Exome sequencing in mostly consanguineous Arab
families with neurologic disease provides a high potential molecular
diagnosis rate</article-title>
<source/>BMC Med Genomics
          <year>2016</year>
<volume>9</volume>
<fpage>42</fpage>
<pub-id pub-id-type="pmid">27435318</pub-id>
</element-citation>
</ref>
<ref id="CR29">
<label>29.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>LELM</surname>
<given-names>Vissers</given-names>
</name>
<name>
<surname>van Nimwegen</surname>
<given-names>KJM</given-names>
</name>
<name>
<surname>Schieving</surname>
<given-names>JH</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A clinical utility study of exome sequencing versus
conventional genetic testing in pediatric neurology</article-title>
<source/>Genet Med
          <year>2017</year>
<volume>19</volume>
<fpage>1055</fpage>
<lpage>1063</lpage>
<pub-id pub-id-type="pmid">28333917</pub-id>
</element-citation>
</ref>
<ref id="CR30">
<label>30.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sun</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Ruivenkamp</surname>
<given-names>CAL</given-names>
</name>
<name>
<surname>Hoffer</surname>
<given-names>MJV</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Next-generation diagnostics: gene panel, exome, or
whole genome?</article-title>
<source/>Hum Mutat
          <year>2015</year>
<volume>36</volume>
<fpage>648</fpage>
<lpage>655</lpage>
<pub-id pub-id-type="pmid">25772376</pub-id>
</element-citation>
</ref>
<ref id="CR31">
<label>31.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xue</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Ankala</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Wilcox</surname>
<given-names>WR</given-names>
</name>
<name>
<surname>Hegde</surname>
<given-names>MR</given-names>
</name>
</person-group>
<article-title>Solving the molecular diagnostic testing conundrum
for Mendelian disorders in the era of next-generation sequencing:
single-gene, gene panel, or exome/genome sequencing</article-title>
<source/>Genet Med
          <year>2015</year>
<volume>17</volume>
<fpage>444</fpage>
<lpage>451</lpage>
<pub-id pub-id-type="pmid">25232854</pub-id>
</element-citation>
</ref>
<ref id="CR32">
<label>32.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wright</surname>
<given-names>CF</given-names>
</name>
<name>
<surname>FitzPatrick</surname>
<given-names>DR</given-names>
</name>
<name>
<surname>Firth</surname>
<given-names>HV</given-names>
</name>
</person-group>
<article-title>Paediatric genomics: diagnosing rare disease in
children</article-title>
<source/>Nat Rev Genet
          <year>2018</year>
<volume>19</volume>
<fpage>253</fpage>
<lpage>268</lpage>
<pub-id pub-id-type="pmid">29398702</pub-id>
</element-citation>
</ref>
<ref id="CR33">
<label>33.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Deignan</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Dorrani</surname>
<given-names>N</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Clinical exome sequencing for genetic identification
of rare Mendelian disorders</article-title>
<source/>JAMA
          <year>2014</year>
<volume>312</volume>
<fpage>1880</fpage>
<lpage>1887</lpage>
<pub-id pub-id-type="pmid">25326637</pub-id>
</element-citation>
</ref>
<ref id="CR34">
<label>34.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kalia</surname>
<given-names>SS</given-names>
</name>
<name>
<surname>Adelman</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Bale</surname>
<given-names>SJ</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Recommendations for reporting of secondary findings
in clinical exome and genome sequencing, 2016 update (ACMG SFv2.0): a policy
statement of the American College of Medical Genetics and
Genomics</article-title>
<source/>Genet Med
          <year>2017</year>
<volume>19</volume>
<fpage>249</fpage>
<lpage>255</lpage>
<pub-id pub-id-type="pmid">27854360</pub-id>
</element-citation>
</ref>
<ref id="CR35">
<label>35.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Harrison</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Dolinsky</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Knight Johnson</surname>
<given-names>AE</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Clinical laboratories collaborate to resolve
differences in variant interpretations submitted to ClinVar</article-title>
<source/>Genet Med
          <year>2017</year>
<volume>19</volume>
<fpage>1096</fpage>
<lpage>1104</lpage>
<pub-id pub-id-type="pmid">28301460</pub-id>
</element-citation>
</ref>
<ref id="CR36">
<label>36.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>J-C</given-names>
</name>
<name>
<surname>Radcliff</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Coe</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Mahon</surname>
<given-names>LW</given-names>
</name>
</person-group>
<article-title>Effects of platforms, size filter cutoffs, and
targeted regions of cytogenomic microarray on detection of copy number
variants and uniparental disomy in prenatal diagnosis: results from 5026
pregnancies</article-title>
<source/>Prenat Diagn
          <year>2019</year>
<volume>39</volume>
<fpage>137</fpage>
<lpage>156</lpage>
<pub-id pub-id-type="pmid">30734327</pub-id>
</element-citation>
</ref>
<ref id="CR37">
<label>37.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Petrovski</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Aggarwal</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Giordano</surname>
<given-names>JL</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Whole-exome sequencing in the evaluation of fetal
structural anomalies: a prospective cohort study</article-title>
<source/>Lancet
          <year>2019</year>
<volume>393</volume>
<fpage>758</fpage>
<lpage>767</lpage>
<pub-id pub-id-type="pmid">30712878</pub-id>
</element-citation>
</ref>
<ref id="CR38">
<label>38.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Thevenon</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Duffourd</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Masurel-Paulet</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Diagnostic odyssey in severe neurodevelopmental
disorders: toward clinical whole-exome sequencing as a first-line diagnostic
test</article-title>
<source/>Clin Genet
          <year>2016</year>
<volume>89</volume>
<fpage>700</fpage>
<lpage>707</lpage>
<pub-id pub-id-type="pmid">26757139</pub-id>
</element-citation>
</ref>
<ref id="CR39">
<label>39.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Soden</surname>
<given-names>SE</given-names>
</name>
<name>
<surname>Saunders</surname>
<given-names>CJ</given-names>
</name>
<name>
<surname>Willig</surname>
<given-names>LK</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Effectiveness of exome and genome sequencing guided
by acuity of illness for diagnosis of neurodevelopmental
disorders</article-title>
<source/>Sci Transl Med
          <year>2014</year>
<volume>6</volume>
<fpage>265ra168</fpage>
<pub-id pub-id-type="pmid">25473036</pub-id>
</element-citation>
</ref>
<ref id="CR40">
<label>40.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Richards</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Aziz</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Bale</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Standards and guidelines for the interpretation of
sequence variants: a joint consensus recommendation of the American College
of Medical Genetics and Genomics and the Association for Molecular
Pathology</article-title>
<source/>Genet Med
          <year>2015</year>
<volume>17</volume>
<fpage>405</fpage>
<lpage>424</lpage>
<pub-id pub-id-type="pmid">25741868</pub-id>
</element-citation>
</ref>
<ref id="CR41">
<label>41.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Anazi</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Maddirevula</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Faqeih</surname>
<given-names>E</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Clinical genomics expands the morbid genome of
intellectual disability and offers a high diagnostic yield</article-title>
<source/>Mol Psychiatry.
          <year>2017</year>
<volume>22</volume>
<fpage>615</fpage>
<lpage>624</lpage>
<pub-id pub-id-type="pmid">27431290</pub-id>
</element-citation>
</ref>
<ref id="CR42">
<label>42.</label>
<mixed-citation publication-type="other">Baldridge D, Heeley J, Vineyard M, et al. The Exome clinic and the
role of medical genetics expertise in the interpretation of exome sequencing
results. Genet Med. 2017;191040–1048</mixed-citation>
</ref>
<ref id="CR43">
<label>43.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Butler</surname>
<given-names>MG</given-names>
</name>
<name>
<surname>Rafi</surname>
<given-names>SK</given-names>
</name>
<name>
<surname>Hossain</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Stephan</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Manzardo</surname>
<given-names>AM</given-names>
</name>
</person-group>
<article-title>Whole exome sequencing in females with autism
implicates novel and candidate genes</article-title>
<source/>Int J Mol Sci
          <year>2015</year>
<volume>16</volume>
<fpage>1312</fpage>
<lpage>1335</lpage>
<pub-id pub-id-type="pmid">25574603</pub-id>
</element-citation>
</ref>
<ref id="CR44">
<label>44.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Codina-Solà</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Rodríguez-Santiago</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Homs</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Integrated analysis of whole-exome sequencing and
transcriptome profiling in males with autism spectrum
disorders</article-title>
<source/>Mol Autism.
          <year>2015</year>
<volume>6</volume>
<fpage>21</fpage>
<pub-id pub-id-type="pmid">25969726</pub-id>
</element-citation>
</ref>
<ref id="CR45">
<label>45.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Evers</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Staufner</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Granzow</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Impact of clinical exomes in neurodevelopmental and
neurometabolic disorders</article-title>
<source/>Mol Genet Metab
          <year>2017</year>
<volume>121</volume>
<fpage>297307</fpage>
</element-citation>
</ref>
<ref id="CR46">
<label>46.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Helsmoortel</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Vandeweyer</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Ordoukhanian</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Van Nieuwerburgh</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Van der Aa</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Kooy</surname>
<given-names>RF</given-names>
</name>
</person-group>
<article-title>Challenges and opportunities in the investigation of
unexplained intellectual disability using family-based whole-exome
sequencing</article-title>
<source/>Clin Genet.
          <year>2015</year>
<volume>88</volume>
<fpage>140</fpage>
<lpage>148</lpage>
<pub-id pub-id-type="pmid">25081361</pub-id>
</element-citation>
</ref>
<ref id="CR47">
<label>47.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Iglesias</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Anyane-Yeboa</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Wynn</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The usefulness of whole-exome sequencing in routine
clinical practice</article-title>
<source/>Genet Med.
          <year>2014</year>
<volume>16</volume>
<fpage>922</fpage>
<lpage>931</lpage>
<pub-id pub-id-type="pmid">24901346</pub-id>
</element-citation>
</ref>
<ref id="CR48">
<label>48.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kuperberg</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Lev</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Blumkin</surname>
<given-names>L</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Utility of whole exome sequencing for genetic
diagnosis of previously undiagnosed pediatric neurology
patients</article-title>
<source/>J Child Neurol
          <year>2016</year>
<volume>31</volume>
<fpage>1534</fpage>
<lpage>1539</lpage>
<pub-id pub-id-type="pmid">27572814</pub-id>
</element-citation>
</ref>
<ref id="CR49">
<label>49.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Monroe</surname>
<given-names>GR</given-names>
</name>
<name>
<surname>Frederix</surname>
<given-names>GW</given-names>
</name>
<name>
<surname>Savelberg</surname>
<given-names>SMC</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Effectiveness of whole-exome sequencing and costs of
the traditional diagnostic trajectory in children with intellectual
disability</article-title>
<source/>Genet Med.
          <year>2016</year>
<volume>18</volume>
<fpage>949</fpage>
<lpage>956</lpage>
<pub-id pub-id-type="pmid">26845106</pub-id>
</element-citation>
</ref>
<ref id="CR50">
<label>50.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nolan</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Carlson</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Whole exome sequencing in pediatric neurology
patients: clinical implications and estimated cost analysis</article-title>
<source/>J Child Neurol
          <year>2016</year>
<volume>31</volume>
<fpage>887</fpage>
<lpage>894</lpage>
<pub-id pub-id-type="pmid">26863999</pub-id>
</element-citation>
</ref>
<ref id="CR51">
<label>51.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Prasad</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Sdano</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Vanzo</surname>
<given-names>RJ</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Clinical utility of exome sequencing in individuals
with large homozygous regions detected by chromosomal microarray
analysis</article-title>
<source/>BMC Med Genet
          <year>2018</year>
<volume>19</volume>
<fpage>46</fpage>
<pub-id pub-id-type="pmid">29554876</pub-id>
</element-citation>
</ref>
<ref id="CR52">
<label>52.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Preikšaitienė</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Ambrozaitytė</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Maldžienė</surname>
<given-names>Ž</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Identification of genetic causes of congenital
neurodevelopmental disorders using genome wide molecular
technologies</article-title>
<source/>Acta Med Litu
          <year>2016</year>
<volume>23</volume>
<fpage>73</fpage>
<lpage>85</lpage>
<pub-id pub-id-type="pmid">28356794</pub-id>
</element-citation>
</ref>
<ref id="CR53">
<label>53.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Riazuddin</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Hussain</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Razzaq</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Exome sequencing of Pakistani consanguineous
families identifies 30 novel candidate genes for recessive intellectual
disability</article-title>
<source/>Mol Psychiatry.
          <year>2017</year>
<volume>22</volume>
<fpage>1604</fpage>
<lpage>1614</lpage>
<pub-id pub-id-type="pmid">27457812</pub-id>
</element-citation>
</ref>
<ref id="CR54">
<label>54.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rossi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>El-Khechen</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Black</surname>
<given-names>MH</given-names>
</name>
<name>
<surname>Farwell Hagman</surname>
<given-names>KD</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Powis</surname>
<given-names>Z</given-names>
</name>
</person-group>
<article-title>Outcomes of diagnostic exome sequencing in patients
with diagnosed or suspected autism spectrum disorders</article-title>
<source/>Pediatr Neurol.
          <year>2017</year>
<volume>70</volume>
<fpage>34</fpage>
<lpage>43.e2</lpage>
<pub-id pub-id-type="pmid">28330790</pub-id>
</element-citation>
</ref>
<ref id="CR55">
<label>55.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Srivastava</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Cohen</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Vernon</surname>
<given-names>H</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Clinical whole exome sequencing in child neurology
practice</article-title>
<source/>Ann Neurol.
          <year>2014</year>
<volume>76</volume>
<fpage>473</fpage>
<lpage>483</lpage>
<pub-id pub-id-type="pmid">25131622</pub-id>
</element-citation>
</ref>
<ref id="CR56">
<label>56.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tammimies</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Marshall</surname>
<given-names>CR</given-names>
</name>
<name>
<surname>Walker</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Molecular diagnostic yield of chromosomal microarray
analysis and whole-exome sequencing in children with autism spectrum
disorder</article-title>
<source/>JAMA.
          <year>2015</year>
<volume>314</volume>
<fpage>895</fpage>
<lpage>903</lpage>
<pub-id pub-id-type="pmid">26325558</pub-id>
</element-citation>
</ref>
<ref id="CR57">
<label>57.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bramswig</surname>
<given-names>NC</given-names>
</name>
<name>
<surname>Lüdecke</surname>
<given-names>H-J</given-names>
</name>
<name>
<surname>Alanay</surname>
<given-names>Y</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Exome sequencing unravels unexpected differential
diagnoses in individuals with the tentative diagnosis of Coffin-Siris and
Nicolaides-Baraitser syndromes</article-title>
<source/>Hum Genet.
          <year>2015</year>
<volume>134</volume>
<fpage>553</fpage>
<lpage>568</lpage>
<pub-id pub-id-type="pmid">25724810</pub-id>
</element-citation>
</ref>
<ref id="CR58">
<label>58.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Campeau</surname>
<given-names>PM</given-names>
</name>
<name>
<surname>Kasperaviciute</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>JT</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The genetic basis of DOORS syndrome: an
exome-sequencing study</article-title>
<source/>Lancet Neurol.
          <year>2014</year>
<volume>13</volume>
<fpage>44</fpage>
<lpage>58</lpage>
<pub-id pub-id-type="pmid">24291220</pub-id>
</element-citation>
</ref>
<ref id="CR59">
<label>59.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gauthier-Vasserot</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Thauvin-Robinet</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Bruel</surname>
<given-names>A-L</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Application of whole-exome sequencing to unravel the
molecular basis of undiagnosed syndromic congenital neutropenia with
intellectual disability</article-title>
<source/>Am J Med Genet A
          <year>2017</year>
<volume>173</volume>
<fpage>62</fpage>
<lpage>71</lpage>
<pub-id pub-id-type="pmid">27615324</pub-id>
</element-citation>
</ref>
<ref id="CR60">
<label>60.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lopes</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Barbosa</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ameur</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Identification of novel genetic causes of Rett
syndrome-like phenotypes</article-title>
<source/>J Med Genet
          <year>2016</year>
<volume>53</volume>
<fpage>190</fpage>
<lpage>199</lpage>
<pub-id pub-id-type="pmid">26740508</pub-id>
</element-citation>
</ref>
<ref id="CR61">
<label>61.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Olson</surname>
<given-names>HE</given-names>
</name>
<name>
<surname>Tambunan</surname>
<given-names>D</given-names>
</name>
<name>
<surname>LaCoursiere</surname>
<given-names>C</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Mutations in epilepsy and intellectual disability
genes in patients with features of Rett syndrome</article-title>
<source/>Am J Med Genet A
          <year>2015</year>
<volume>167A</volume>
<fpage>2017</fpage>
<lpage>2025</lpage>
<pub-id pub-id-type="pmid">25914188</pub-id>
</element-citation>
</ref>
<ref id="CR62">
<label>62.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rump</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Jazayeri</surname>
<given-names>O</given-names>
</name>
<name>
<surname>van Dijk-Bos</surname>
<given-names>KK</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Whole-exome sequencing is a powerful approach for
establishing the etiological diagnosis in patients with intellectual
disability and microcephaly</article-title>
<source/>BMC Med Genomics
          <year>2016</year>
<volume>9</volume>
<fpage>7</fpage>
<pub-id pub-id-type="pmid">26846091</pub-id>
</element-citation>
</ref>
<ref id="CR63">
<label>63.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tarailo-Graovac</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Shyr</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Ross</surname>
<given-names>CJ</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Exome sequencing and the management of
neurometabolic disorders</article-title>
<source/>N Engl J Med
          <year>2016</year>
<volume>374</volume>
<fpage>2246</fpage>
<lpage>2255</lpage>
<pub-id pub-id-type="pmid">27276562</pub-id>
</element-citation>
</ref>
<ref id="CR64">
<label>64.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yeung</surname>
<given-names>KS</given-names>
</name>
<name>
<surname>Tso</surname>
<given-names>WWY</given-names>
</name>
<name>
<surname>Ip</surname>
<given-names>JJK</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Identification of mutations in the PI3K-AKT-mTOR
signalling pathway in patients with macrocephaly and developmental delay
and/or autism</article-title>
<source/>Mol Autism.
          <year>2017</year>
<volume>8</volume>
<fpage>66</fpage>
<pub-id pub-id-type="pmid">29296277</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>